Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.

Oral steroids provide clinically insignificant benefits in NAAION

07 Oct 2018

Use of oral steroids in acute nonarteritic anterior ischaemic optic neuropathy (NAAION) does not lead to significant improvements in visual acuity at 6 months, but it significantly enhances resolution of disc oedema and allows greater progress in visual evoked response (VER) parameters, reports a recent study.

A total of 38 patients with acute nondiabetic NAAION were recruited in this randomized double-blind clinical trial that examined the role of oral steroid therapy in the treatment of such condition. Participants were divided into two arms of 19 patients each, with one arm constituting the cases and the other the controls.

NAAION patients received oral steroid therapy and were designated the steroid group, while control participants received placebo and were designated the nonsteroid group. The authors performed best-corrected visual acuity (BCVA), VER and optical coherence tomography (OCT) assessments at baseline, 1 month, 3 months and 6 months after recruitment into the trial.

There were significant improvements in BCVA, VER latency and resolution of disc oedema on OCT parameters over 6 months in both groups.

No statistically significant difference was observed in terms of visual acuity, but VER was better in the steroid group (p=0.011). The steroid group also had a greater percentage improvement in BCVA (p=0.02), VER amplitude (p=0.02) and VER latency (p=0.04), as well as a faster resolution of disc oedema on OCT at 1-month follow-up.

“This subtle benefit of oral steroids in NAAION is clinically unimportant and does not provide support for its use,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Low-dose administrations of haloperidol after thoracic surgery does not appear to prevent postoperative delirium, according to a new study.
4 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 6 days ago
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.